90-Second Read: Dyadic and Scripps Research Collaborate on Rapid-Response Hantavirus Antibody and Vaccine Development

Collaboration Leverages Prior Andes, Marburg and Ebola Virus Research and Dyadic's C1 Platform Capabilities for Fast, Scalable Biologic ProductionJUPITER, Fla., May 28, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. Dyadic has also previously demonstrated GMP-compliant manufacturing and Phase 1 clinical evaluation of biologics produced using its C1 platform as part of earlier infectious disease initiatives. Forward-looking statements involve many risks, uncertainties, or other factors beyond Dyadic's control.

Together, these programs continue to generate data that support the potential advantages of the C1 platform, including compressed development timelines, scalable microbial fermentation, and streamlined manufacturing processes. Additional studies have shown that C1-produced monoclonal antibodies can achieve binding and neutralization properties comparable to antibodies produced in traditional mammalian systems. Dyadic recently highlighted growing commercial activity with recombinant proteins and enzymes in non-pharmaceutical applications, including animal-free proteins for life sciences, cell culture media, nutrition, wellness, and industrial markets.

Forward-looking statements generally can be identified by use of the words "expect," "should," "intend," "anticipate," "will," "project," "may," "might," "potential," or "continue" and other similar terms or variations of them or similar terminology. Dyadic International, Inc., and its subsidiaries caution readers that any forward-looking information is not a guarantee of future performance and that actual results could differ materially from those contained in the forward-looking information.